Recurrent respiratory papillomatosis can occur anywhere in the respiratory tract, although the larynx and vocal cords are the most commonly affected (laryngeal papillomatosis). The condition affects the mouth (oral cavity), trachea, and bronchi less frequently. Only a small percentage of these tumors move to the lungs.
- Cidofovir is one of the most commonly used antiviral drugs for the treatment of recurrent respiratory papillomatosis. This is an adjuvant therapy that is injected into the lesions directly (intralesional).
- Some people with recurrent respiratory papillomatosis, particularly those with large papillomas, have been treated using photodynamic therapy, a method in which a medication known as a photosensitizer is combined with a special type of light.
- A specific wavelength of light is utilized to activate the medication, which binds to oxygen and produces a chemical that kills the cells.
- Additional medications are being researched as possible adjuvant therapy for people who have RRP. Bevacizumab, a monoclonal antibody, is one of these medications.
- Bevacizumab can be injected into papilloma growths and used in combination with a pulse dye laser to stop papillomas from forming new blood vessels.
- This method of treatment appears to be particularly effective in patients with recurrent papillomas of the larynx and trachea.